Visual Findings of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Cardiac Sarcoidosis

Objective The purpose of this study was to evaluate the cardiac sarcoidosis (CS) activity according to the classified visual uptake pattern using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and assess the uptake pattern based on the free fatty acid (FFA)...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine Vol. 53; no. 18; pp. 2041 - 2049
Main Authors Kubota, Kazuo, Minamimoto, Ryogo, Morooka, Miyako, Ito, Kimiteru, Okazaki, Osamu, Hiroe, Michiaki
Format Journal Article
LanguageEnglish
Published The Japanese Society of Internal Medicine 2014
Subjects
Online AccessGet full text
ISSN0918-2918
1349-7235
DOI10.2169/internalmedicine.53.2491

Cover

Abstract Objective The purpose of this study was to evaluate the cardiac sarcoidosis (CS) activity according to the classified visual uptake pattern using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and assess the uptake pattern based on the free fatty acid (FFA) levels. Methods Nineteen CS subjects who underwent 18F-FDG PET/CT examinations with heparin loading (HL) were recruited to evaluate their CS activity. The 18F-FDG uptake in the heart was classified into five categories ("none," "diffuse" and "diffuse at base," regarded as stable CS, and "focal" and "focal on diffuse," regarded as de novo or worsening CS). The subject data were compared with the 18F-FDG PET/CT findings in 13 healthy volunteers. The FFA serum levels were assessed in 10 patients with CS and all volunteers. Results The sensitivity and specificity of 18F-FDG PET/CT with HL were 75% (6/8) and 73% (8/11), respectively. The major pattern of cardiac 18F-FDG uptake was "diffuse at base." Ten of the 32 subjects, including the control group, exhibited this pattern. The FFA serum levels before heparin administration were statistically significantly different between the patients with the "none" pattern and those with the "diffuse" and "diffuse at base" patterns. There were no significant correlations between the FFA serum levels after heparin administration and the 18F-FDG uptake patterns. Conclusion "Diffuse at base" is the major 18F-FDG uptake pattern associated with inadequate physiologic 18F-FDG suppression. This pattern should be carefully interpreted when examining the 18F-FDG PET/CT images of CS patients. Additionally, increased FFAs levels associated with HL may not completely suppress the physiologic myocardial FDG uptake.
AbstractList Objective The purpose of this study was to evaluate the cardiac sarcoidosis (CS) activity according to the classified visual uptake pattern using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and assess the uptake pattern based on the free fatty acid (FFA) levels. Methods Nineteen CS subjects who underwent 18F-FDG PET/CT examinations with heparin loading (HL) were recruited to evaluate their CS activity. The 18F-FDG uptake in the heart was classified into five categories ("none," "diffuse" and "diffuse at base," regarded as stable CS, and "focal" and "focal on diffuse," regarded as de novo or worsening CS). The subject data were compared with the 18F-FDG PET/CT findings in 13 healthy volunteers. The FFA serum levels were assessed in 10 patients with CS and all volunteers. Results The sensitivity and specificity of 18F-FDG PET/CT with HL were 75% (6/8) and 73% (8/11), respectively. The major pattern of cardiac 18F-FDG uptake was "diffuse at base." Ten of the 32 subjects, including the control group, exhibited this pattern. The FFA serum levels before heparin administration were statistically significantly different between the patients with the "none" pattern and those with the "diffuse" and "diffuse at base" patterns. There were no significant correlations between the FFA serum levels after heparin administration and the 18F-FDG uptake patterns. Conclusion "Diffuse at base" is the major 18F-FDG uptake pattern associated with inadequate physiologic 18F-FDG suppression. This pattern should be carefully interpreted when examining the 18F-FDG PET/CT images of CS patients. Additionally, increased FFAs levels associated with HL may not completely suppress the physiologic myocardial FDG uptake.
Author Okazaki, Osamu
Ito, Kimiteru
Morooka, Miyako
Hiroe, Michiaki
Minamimoto, Ryogo
Kubota, Kazuo
Author_xml – sequence: 1
  fullname: Kubota, Kazuo
  organization: Department of Nuclear Medicine, National Center for Global Health and Medicine, Japan
– sequence: 1
  fullname: Minamimoto, Ryogo
  organization: Department of Nuclear Medicine, National Center for Global Health and Medicine, Japan
– sequence: 1
  fullname: Morooka, Miyako
  organization: Department of Nuclear Medicine, National Center for Global Health and Medicine, Japan
– sequence: 1
  fullname: Ito, Kimiteru
  organization: Department of Radiology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Japan
– sequence: 1
  fullname: Okazaki, Osamu
  organization: Department of Cardiology, National Center for Global Health and Medicine, Japan
– sequence: 1
  fullname: Hiroe, Michiaki
  organization: Department of Cardiology, National Center for Global Health and Medicine, Japan
BookMark eNqNkFtLAzEQhYMoWC__IX9gay57y4sgxapQULD4uozZaTuym5QkRfvkX3dLi4j44MvMcDjnYzhn7Nh5h4xxKcZKluaKXMLgoOuxJUsOx4Ueq9zIIzaSOjdZpXRxzEbCyDpTwzhlZzG-CaHryqgR-3yhuIGOT8m15JaR-wWX9TSbdhsffIv-Y7vsNtZH5E8-Ugre8dueYqThmPveLwOsV9urie_Xm4TtD42T40-QCF2K_J3Sik8gtASWP0OwntqBFy_YyQK6iJeHfc7m09v55D6bPd49TG5mmVVCuKyo8lIIKUGUhXzNK10OgjRtZaxGJXRZC2x1rl41GKgGn0RQwqDRxQKV1Ofseo-1wccYcNFYSsNv3qUA1DVSNLs2m99tNoVudm0OgPoXYB2oh7D9T_RxH32LCZb4HYSQyHb4Z1DWu3kgfDvtCkKDTn8B_NKjQw
CitedBy_id crossref_primary_10_1007_s12350_018_01582_y
crossref_primary_10_1097_RLU_0000000000001465
crossref_primary_10_1007_s00259_018_4195_9
crossref_primary_10_1536_ihj_17_492
crossref_primary_10_4070_kcj_2021_0104
crossref_primary_10_1016_j_crad_2018_09_015
crossref_primary_10_1016_j_jcmg_2023_05_017
crossref_primary_10_1007_s12350_018_1404_7
crossref_primary_10_1007_s12410_019_9485_5
crossref_primary_10_1007_s12350_017_0962_4
crossref_primary_10_1007_s12350_017_1122_6
crossref_primary_10_1148_radiol_213170
crossref_primary_10_1016_j_clinimag_2024_110248
Cites_doi 10.1056/NEJM199704243361706
10.1097/RLU.0b013e318266cb25
10.1007/s12149-013-0721-9
10.1093/eurheartj/ehi180
10.1016/j.jcmg.2010.09.015
10.1007/s12350-009-9110-0
10.1378/chest.103.1.253
10.1111/j.1445-5994.2007.01590.x
10.1016/S0002-9149(01)01978-6
10.1007/s00259-011-1832-y
10.1007/s12350-013-9798-8
10.1186/2191-219X-4-1
10.2967/jnumed.107.041574
10.1016/S0002-9149(98)00377-4
10.1016/0735-1097(90)92035-Z
10.1111/j.1749-6632.1976.tb47058.x
ContentType Journal Article
Copyright 2014 by The Japanese Society of Internal Medicine
Copyright_xml – notice: 2014 by The Japanese Society of Internal Medicine
DBID AAYXX
CITATION
DOI 10.2169/internalmedicine.53.2491
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1349-7235
EndPage 2049
ExternalDocumentID 10_2169_internalmedicine_53_2491
article_internalmedicine_53_18_53_53_2491_article_char_en
GroupedDBID ---
.55
29J
2WC
3O-
53G
5GY
ACPRK
ADBBV
ADRAZ
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CS3
DIK
DU5
EBS
EJD
EMOBN
F5P
HYE
JSF
JSH
M48
OK1
OVT
P2P
PGMZT
RJT
RNS
RPM
RZJ
TKC
TR2
X7M
XSB
AAYXX
CITATION
ID FETCH-LOGICAL-c200n-57460011a0651b473674619d79c3e203680ed342b3a9a711a1ea209e935fe213
ISSN 0918-2918
IngestDate Tue Jul 01 01:39:56 EDT 2025
Thu Apr 24 22:54:42 EDT 2025
Wed Sep 03 06:15:01 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 18
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c200n-57460011a0651b473674619d79c3e203680ed342b3a9a711a1ea209e935fe213
OpenAccessLink https://www.jstage.jst.go.jp/article/internalmedicine/53/18/53_53.2491/_article/-char/en
PageCount 9
ParticipantIDs crossref_citationtrail_10_2169_internalmedicine_53_2491
crossref_primary_10_2169_internalmedicine_53_2491
jstage_primary_article_internalmedicine_53_18_53_53_2491_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014
PublicationDateYYYYMMDD 2014-01-01
PublicationDate_xml – year: 2014
  text: 2014
PublicationDecade 2010
PublicationTitle Internal Medicine
PublicationTitleAlternate Intern. Med.
PublicationYear 2014
Publisher The Japanese Society of Internal Medicine
Publisher_xml – name: The Japanese Society of Internal Medicine
References 8. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 38: 1773-1783, 2011.
20. Gropler RJ, Siegel BA, Lee KJ, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 31: 1749-1756, 1990.
6. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88: 1006-1010, 2001.
5. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann NY Acad Sci 278: 455-469, 1976.
22. Tamaki N, Yonekura Y, Kawamoto M, et al. Simple quantification of regional myocardial uptake of fluorine-18-deoxyglucose in the fasting condition. J Nucl Med 32: 2152-2157, 1991.
9. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med 44: 1030-1036, 2003.
10. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26: 1538-1543, 2005.
23. Minamimoto R, Morooka M, Miyata Y, et al. Incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening. Ann Nucl Med 27: 572-580, 2013.
2. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 103: 253-258, 1993.
19. Sugisaki K. Diagnostic Guidelines and Criteria for Sarcoidosis-2006. Nihon Kokyuki Gakkai Zasshi 46: 768-780, 2008 (in Japanese).
17. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 4: 1, 2014.
21. Inglese E, Leva L, Matheoud R, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med 48: 1662-1669, 2007.
11. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 16: 801-810, 2009.
13. Ishimaru S, Tsujino I, Sakaue S, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22: 234-235, 2005.
15. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33: 1972-1980, 1992.
1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 336: 1224-1234, 1997.
3. Habersberger J, Manins V, Taylor AJ. Cardiac sarcoidosis. Intern Med J 38: 270-277, 2008.
14. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 3: 1219-1228, 2010.
4. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58: 1204-1211, 1978.
12. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45: 1989-1998, 2004.
7. Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 82: 537-540, 1998.
16. Ito K, Morooka M, Okazaki O, Minaminoto R, Kubota K, Hiroe M. Efficacy of Heparin Loading During an 18F-FDG PET/CT Examination to Search for Cardiac Sarcoidosis Activity. Clin Nucl Med 38: 128-130, 2013.
18. Gormsen LC, Christensen NL, Bendstrup E, Tolbod LP, Nielsen SS. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J Nucl Cardiol 20: 1108-1115, 2013.
11
22
12
23
13
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
10
21
References_xml – reference: 17. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 4: 1, 2014.
– reference: 18. Gormsen LC, Christensen NL, Bendstrup E, Tolbod LP, Nielsen SS. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J Nucl Cardiol 20: 1108-1115, 2013.
– reference: 21. Inglese E, Leva L, Matheoud R, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med 48: 1662-1669, 2007.
– reference: 16. Ito K, Morooka M, Okazaki O, Minaminoto R, Kubota K, Hiroe M. Efficacy of Heparin Loading During an 18F-FDG PET/CT Examination to Search for Cardiac Sarcoidosis Activity. Clin Nucl Med 38: 128-130, 2013.
– reference: 20. Gropler RJ, Siegel BA, Lee KJ, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 31: 1749-1756, 1990.
– reference: 1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 336: 1224-1234, 1997.
– reference: 2. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 103: 253-258, 1993.
– reference: 5. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann NY Acad Sci 278: 455-469, 1976.
– reference: 9. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med 44: 1030-1036, 2003.
– reference: 19. Sugisaki K. Diagnostic Guidelines and Criteria for Sarcoidosis-2006. Nihon Kokyuki Gakkai Zasshi 46: 768-780, 2008 (in Japanese).
– reference: 14. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 3: 1219-1228, 2010.
– reference: 22. Tamaki N, Yonekura Y, Kawamoto M, et al. Simple quantification of regional myocardial uptake of fluorine-18-deoxyglucose in the fasting condition. J Nucl Med 32: 2152-2157, 1991.
– reference: 4. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58: 1204-1211, 1978.
– reference: 11. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 16: 801-810, 2009.
– reference: 3. Habersberger J, Manins V, Taylor AJ. Cardiac sarcoidosis. Intern Med J 38: 270-277, 2008.
– reference: 12. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45: 1989-1998, 2004.
– reference: 13. Ishimaru S, Tsujino I, Sakaue S, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22: 234-235, 2005.
– reference: 8. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 38: 1773-1783, 2011.
– reference: 23. Minamimoto R, Morooka M, Miyata Y, et al. Incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening. Ann Nucl Med 27: 572-580, 2013.
– reference: 10. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26: 1538-1543, 2005.
– reference: 7. Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 82: 537-540, 1998.
– reference: 15. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33: 1972-1980, 1992.
– reference: 6. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88: 1006-1010, 2001.
– ident: 1
  doi: 10.1056/NEJM199704243361706
– ident: 16
  doi: 10.1097/RLU.0b013e318266cb25
– ident: 23
  doi: 10.1007/s12149-013-0721-9
– ident: 4
– ident: 10
  doi: 10.1093/eurheartj/ehi180
– ident: 14
  doi: 10.1016/j.jcmg.2010.09.015
– ident: 11
  doi: 10.1007/s12350-009-9110-0
– ident: 12
– ident: 2
  doi: 10.1378/chest.103.1.253
– ident: 3
  doi: 10.1111/j.1445-5994.2007.01590.x
– ident: 6
  doi: 10.1016/S0002-9149(01)01978-6
– ident: 8
  doi: 10.1007/s00259-011-1832-y
– ident: 19
– ident: 13
– ident: 15
– ident: 18
  doi: 10.1007/s12350-013-9798-8
– ident: 17
  doi: 10.1186/2191-219X-4-1
– ident: 21
  doi: 10.2967/jnumed.107.041574
– ident: 7
  doi: 10.1016/S0002-9149(98)00377-4
– ident: 20
  doi: 10.1016/0735-1097(90)92035-Z
– ident: 9
– ident: 5
  doi: 10.1111/j.1749-6632.1976.tb47058.x
– ident: 22
SSID ssj0038792
Score 1.9939415
Snippet Objective The purpose of this study was to evaluate the cardiac sarcoidosis (CS) activity according to the classified visual uptake pattern using...
SourceID crossref
jstage
SourceType Enrichment Source
Index Database
Publisher
StartPage 2041
SubjectTerms cardiac sarcoidosis
free fatty acid
heparin loading
PET
physiologic uptake
Title Visual Findings of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Cardiac Sarcoidosis
URI https://www.jstage.jst.go.jp/article/internalmedicine/53/18/53_53.2491/_article/-char/en
Volume 53
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Internal Medicine, 2014, Vol.53(18), pp.2041-2049
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1349-7235
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0038792
  issn: 0918-2918
  databaseCode: DIK
  dateStart: 19920101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKghAXxFO7vOQDt1W6cey8jmi1VZdVYQ8B7S1KYlcq7caobSTaCz-QP8VMbKdhVcSyl6gdxdPG82U8Hs-DkPeBjCNR-JUXJpHwROkrL5E89bhSIo1KWPHa6vqTT9H4i_h4FV4NBr96UUvNuhxW2715JXeRKtBArpgl-x-S7ZgCAT6DfOEKEobrrWT8dbbC7I_RrE1NaYMyWDLyRotGg15U-sfGRaRfYmzWEiR9BnJFB9lxpq9ttWoskWt6O8geFR0hl6boqs2AO23BVKETudIzCRxXfdPW-hYX3XE9Gq-Znm9aZyzGn_a8Dudt96bjiza9atl0rt55sS1MI-3Pq-K6o0_gefS8MHH-m2KudydQpV7brLZto_s-DJM16tyQDLNArA5WRglzkXpxYMqYOC1tSgo7NCZ9neub0ll2_Yav6b61IWARllad2clwczEM-RC2oGy3HroYgBvLZBe8CNsm5JXf5JSHPEdO98j9AJ1DaKGfXzizgCdx26G7e2ATVoacTv72n_6wlR58g-2CCzVsrZ_sCXlsty30g8HgUzJQ9TPycGI5PSc_DRSpgyLVU7ofitRBkToo0h3oThwQezQ6q6kDIkUgUgtE2gPiC5KNzrLTsWd7e3gVvMG1F8YCTW1WgAnMShHzCAgslXFacYWH44mvJBdByYu0iOE-porAT1XKw6kKGH9JDmpdq0NCJVdg84tYqmklKmywxuOyYomQolShL49I7CYxr2zde2y_ssj_JcgjwrqR303tl1uMGRs5dSOsdtg7giV4tUO7OzHfEtTbqzv8_GvyCN8v4yN8Qw7Wy0a9Bat5Xb5r0fgbOM7O_w
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Visual+Findings+of+18F-Fluorodeoxyglucose+Positron+Emission+Tomography%2FComputed+Tomography+in+Patients+with+Cardiac+Sarcoidosis&rft.jtitle=Internal+medicine+%28Tokyo%2C+1992%29&rft.au=Ito%2C+Kimiteru&rft.au=Okazaki%2C+Osamu&rft.au=Morooka%2C+Miyako&rft.au=Kubota%2C+Kazuo&rft.date=2014&rft.issn=0918-2918&rft.eissn=1349-7235&rft.volume=53&rft.issue=18&rft.spage=2041&rft.epage=2049&rft_id=info:doi/10.2169%2Finternalmedicine.53.2491&rft.externalDBID=n%2Fa&rft.externalDocID=10_2169_internalmedicine_53_2491
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-2918&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-2918&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-2918&client=summon